OMER Valuation

Omeros Corp

Add to Watchlist

Advanced Chart

4.140

+0.08(1.970%)1D

Overview
Forecast
Valuation
Earnings

OMER Relative Valuation

OMER's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OMER is overvalued; if below, it's undervalued.

Historical Valuation

Omeros Corp (OMER) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.32 is considered Undervalued compared with the five-year average of -3.80. The fair price of Omeros Corp (OMER) is between 13.25 to 42.79 according to relative valuation methord. Compared to the current price of 4.13 USD , Omeros Corp is Undervalued By 68.83%.

Relative Value

Fair Zone

13.25-42.79

Current Price：4.13

68.83%

Undervalued

-2.55

Trailing

Forward

0.00

EV/EBITDA

Omeros Corp. (OMER) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 154.83. The thresholds are as follows: Strongly Undervalued below -1247.34, Undervalued between -1247.34 and -546.25, Fairly Valued between 855.92 and -546.25, Overvalued between 855.92 and 1557.00, and Strongly Overvalued above 1557.00. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-5.71

EV/EBIT

Omeros Corp. (OMER) has a current EV/EBIT of -5.71. The 5-year average EV/EBIT is -6.08. The thresholds are as follows: Strongly Undervalued below -17.17, Undervalued between -17.17 and -11.63, Fairly Valued between -0.54 and -11.63, Overvalued between -0.54 and 5.01, and Strongly Overvalued above 5.01. The current Forward EV/EBIT of -5.71 falls within the Historic Trend Line -Fairly Valued range.

8.94

Omeros Corp. (OMER) has a current PS of 8.94. The 5-year average PS is 26.76. The thresholds are as follows: Strongly Undervalued below -39.76, Undervalued between -39.76 and -6.50, Fairly Valued between 60.03 and -6.50, Overvalued between 60.03 and 93.29, and Strongly Overvalued above 93.29. The current Forward PS of 8.94 falls within the Historic Trend Line -Fairly Valued range.

-5.04

P/OCF

Omeros Corp. (OMER) has a current P/OCF of -5.04. The 5-year average P/OCF is -19.18. The thresholds are as follows: Strongly Undervalued below -218.41, Undervalued between -218.41 and -118.80, Fairly Valued between 80.43 and -118.80, Overvalued between 80.43 and 180.04, and Strongly Overvalued above 180.04. The current Forward P/OCF of -5.04 falls within the Historic Trend Line -Fairly Valued range.

-3.61

P/FCF

Omeros Corp. (OMER) has a current P/FCF of -3.61. The 5-year average P/FCF is -0.97. The thresholds are as follows: Strongly Undervalued below -15.76, Undervalued between -15.76 and -8.37, Fairly Valued between 6.43 and -8.37, Overvalued between 6.43 and 13.82, and Strongly Overvalued above 13.82. The current Forward P/FCF of -3.61 falls within the Historic Trend Line -Fairly Valued range.

Omeros Corp (OMER) has a current Price-to-Book (P/B) ratio of -1.10. Compared to its 3-year average P/B ratio of -1.53 , the current P/B ratio is approximately -27.64% higher. Relative to its 5-year average P/B ratio of -4.06, the current P/B ratio is about -72.81% higher. Omeros Corp (OMER) has a Forward Free Cash Flow (FCF) yield of approximately -56.36%. Compared to its 3-year average FCF yield of -18.15%, the current FCF yield is approximately 210.58% lower. Relative to its 5-year average FCF yield of -19.09% , the current FCF yield is about 195.25% lower.

-1.12

P/B

Median3y

-1.53

Median5y

-4.06

-52.47

FCF Yield

Median3y

-18.15

Median5y

-19.09

Competitors Valuation Multiple

The average P/S ratio for OMER's competitors is 44.69, providing a benchmark for relative valuation. Omeros Corp Corp (OMER) exhibits a P/S ratio of 8.94, which is -80.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Lifecore Biomedical Inc

Atea Pharmaceuticals Inc

Loss

278.55M

SGMT.O

Sagimet Biosciences Inc

Performance Decomposition

Market capitalization of OMER increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of OMER in the past 1 year is driven by Unknown.